AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 39717667 — intervention group
Group type: EXPERIMENTAL
Intervention: Bintrafusp alfa with chemotherapy (first-line treatment in cohorts A, B, C)
Number of subjects: 0
Study 39717667 — intervention group
Group type: EXPERIMENTAL
Intervention: Bintrafusp alfa with chemotherapy (second-line treatment in cohort D)
Number of subjects: 0
Study 39717698 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent theta burst stimulation (iTBS), 80% motor threshold; 5 sessions per day; 5 days; 3 targets; 18,000 pulses/day over 2 weeks
Number of subjects: 10
Study 39717737 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher percentage of plasmatic palmitic acid (16:0) in cases with liver fibrosis
Number of subjects: 142
Study 39717737 — intervention group
Group type: COMPARATOR
Intervention: Control group (HIV mono-infected individuals without liver fibrosis)
Number of subjects: 142
Study 39717777 — intervention group
Group type: COMPARATOR
Intervention: SM17 (2, 20, 70, 200, 400, 600, 1200 mg)
Number of subjects: 77
Study 39717777 — intervention group
Group type: COMPARATOR
Intervention: SM17 (200, 400, 600 mg) every two weeks (Q2W) for a total of 3 doses
Number of subjects: 77
Study 39717777 — intervention group
Group type: EXPERIMENTAL
Intervention: SM17 (up to 1200 mg)
Number of subjects: 77
Study 39717874 — intervention group
Group type: EXPERIMENTAL
Intervention: Hair cortisol concentrations (HCC)
Number of subjects: 196
Study 39717874 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunological markers (T cell concentration, CD4/CD8 cell ratio, proinflammatory cytokines TNF-α, IL-6, IL-18)
Number of subjects: 196
Study 39717874 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 196
Study 39717993 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide (1.8, 1.2 or 0.6 mg)
Number of subjects: 0
Study 39717993 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 39718172 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly dihydroartemisinin-piperaquine (approximately 2.5 mg per kg bodyweight dihydroartemisinin and 20 mg per kg bodyweight per day piperaquine)
Number of subjects: 724
Study 39718172 — intervention group
Group type: COMPARATOR
Intervention: Monthly sulfadoxine-pyrimethamine (approximately 25 mg per kg bodyweight sulfadoxine and 1.25 mg per kg bodyweight)
Number of subjects: 724
Study 39718172 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly dihydroartemisinin-piperaquine
Number of subjects: 724
Study 39718172 — intervention group
Group type: COMPARATOR
Intervention: Monthly sulfadoxine-pyrimethamine
Number of subjects: 724
Study 39718497 — intervention group
Group type: EXPERIMENTAL
Intervention: nacVI-RADS 3 or higher
Number of subjects: 110
Study 39718497 — intervention group
Group type: EXPERIMENTAL
Intervention: nacVI-RADS
Number of subjects: 110
Study 39718497 — intervention group
Group type: EXPERIMENTAL
Intervention: VI-RADS 3 or higher
Number of subjects: 110
Study 39718497 — intervention group
Group type: EXPERIMENTAL
Intervention: nacVI-RADS scores
Number of subjects: 110
Study 39718599 — intervention group
Group type: EXPERIMENTAL
Intervention: Egg-protein hydrolysate (NWT-03) 5.7 g
Number of subjects: 44
Study 39718599 — intervention group
Group type: COMPARATOR
Intervention: Maltodextrin placebo
Number of subjects: 44
Study 39718747 — intervention group
Group type: EXPERIMENTAL
Intervention: belantamab mafodotin (2.5 mg/kg on Day 1 of each 21-day cycle) plus bortezomib and dexamethasone (Arm A)
Number of subjects: 7
Study 39718747 — intervention group
Group type: EXPERIMENTAL
Intervention: belantamab mafodotin (2.5 mg/kg on Day 1 of the first 28-day cycle; 1.9 mg/kg on Day 1 of subsequent cycles) plus pomalidomide and dexamethasone (Arm B)
Number of subjects: 7
Study 39718983 — intervention group
Group type: EXPERIMENTAL
Intervention: Hippocampal avoidance prophylactic cranial irradiation (HA-PCI)
Number of subjects: 106
Study 39718983 — intervention group
Group type: COMPARATOR
Intervention: Conventional prophylactic cranial irradiation (PCI)
Number of subjects: 106
Study 39718991 — intervention group
Group type: EXPERIMENTAL
Intervention: rVSV-ZEBOV vaccine
Number of subjects: 212
Study 39718991 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 212
Study 39719131 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant pembrolizumab
Number of subjects: 52
Study 39719248 — intervention group
Group type: EXPERIMENTAL
Intervention: Empowerment intervention (phone-based, 3 weekly sessions)
Number of subjects: 400
Study 39719248 — intervention group
Group type: EXPERIMENTAL
Intervention: Education intervention (phone-based, 3 weekly sessions)
Number of subjects: 400
Study 39719276 — intervention group
Group type: EXPERIMENTAL
Intervention: CEOAS index for assessing tooth wear (scores 0-3) and occurrence of enamel defects (scores I-III)
Number of subjects: 0
Study 39719276 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical examinations using the CEOAS index
Number of subjects: 0
Study 39719276 — intervention group
Group type: EXPERIMENTAL
Intervention: Questionnaire addressing general health, sleep quality, dietary habits, oral hygiene habits, and parafunctional habits
Number of subjects: 0
Study 39719276 — intervention group
Group type: EXPERIMENTAL
Intervention: Measurement of vertical dimension of occlusion (VDO)
Number of subjects: 0
Study 39719282 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemonitoring (TM) intervention including immediate feedback on glucose and blood pressure readings, educational videos on exercise and nutrition, and personalised support with TM nurse for 6 months.
Number of subjects: 21
Study 39719288 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate free near-vision glasses and half-day training for smartphone and banking app use
Number of subjects: 484
Study 39719288 — intervention group
Group type: COMPARATOR
Intervention: Glasses and training 12 months later (control)
Number of subjects: 484
Study 39719323 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel ERG devices (RETEval full-field and UTAS multifocal ERG)
Number of subjects: 140
Study 39719323 — intervention group
Group type: COMPARATOR
Intervention: Standard screening tests (spectral-domain optical coherence tomography and autofluorescence)
Number of subjects: 140
Study 39719323 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel ERG devices
Number of subjects: 140
Study 39719417 — intervention group
Group type: EXPERIMENTAL
Intervention: Myectomy
Number of subjects: 173
Study 39719423 — intervention group
Group type: EXPERIMENTAL
Intervention: AccuFFRangio
Number of subjects: 304
Study 39719423 — intervention group
Group type: COMPARATOR
Intervention: FFR
Number of subjects: 304
Study 39719429 — intervention group
Group type: EXPERIMENTAL
Intervention: (R)-1,3-butanediol (BD) 0.5 g/kg
Number of subjects: 12
Study 39719429 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 39719465 — intervention group
Group type: EXPERIMENTAL
Intervention: Text-Based Adherence Game (TAG)
Number of subjects: 60
Study 39719465 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-Care (SOC)
Number of subjects: 60
Study 39719488 — intervention group
Group type: EXPERIMENTAL
Intervention: Elinzanetant 120 mg single dose
Number of subjects: 6
Study 39719502 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept (IVT-AFL) 2 mg
Number of subjects: 496
Study 39719545 — intervention group
Group type: EXPERIMENTAL
Intervention: RENEW intervention using the digital gamification platform Kahoot! administered across eight weekly sessions
Number of subjects: 45
Study 39719545 — intervention group
Group type: EXPERIMENTAL
Intervention: RENEW intervention
Number of subjects: 45
Study 39719625 — intervention group
Group type: EXPERIMENTAL
Intervention: LHS intervention during treatment phase
Number of subjects: 307
Study 39719625 — intervention group
Group type: EXPERIMENTAL
Intervention: LHS intervention during maintenance phase
Number of subjects: 307
Study 39719625 — intervention group
Group type: COMPARATOR
Intervention: Control phase
Number of subjects: 307
Study 39719648 — intervention group
Group type: EXPERIMENTAL
Intervention: Reframe-IT+ intervention group (n=48)
Number of subjects: 1546
Study 39719927 — intervention group
Group type: EXPERIMENTAL
Intervention: PRRBCs
Number of subjects: 321
Study 39719927 — intervention group
Group type: COMPARATOR
Intervention: Conventional RBCs
Number of subjects: 321
Study 39719976 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep brain stimulation (DBS) of the medial pulvinar nucleus (PuM)
Number of subjects: 6
Study 39720009 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Post-Approval Study (PAS)
Number of subjects: 1015
Study 39720009 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-World Data (RWD)
Number of subjects: 1015
Study 39720422 — intervention group
Group type: EXPERIMENTAL
Intervention: PTSD-PRS (Polygenic Risk Score for PTSD)
Number of subjects: 1869
Study 39720422 — intervention group
Group type: EXPERIMENTAL
Intervention: MDD-PRS (Polygenic Risk Score for Major Depressive Disorder)
Number of subjects: 1869
Study 39720440 — intervention group
Group type: EXPERIMENTAL
Intervention: Estimated IQ
Number of subjects: 0
Study 39720440 — intervention group
Group type: EXPERIMENTAL
Intervention: Executive functions
Number of subjects: 0
Study 39720510 — intervention group
Group type: EXPERIMENTAL
Intervention: CNP-106 (COUR nanoparticle)
Number of subjects: 54
Study 39720510 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 39720677 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomarkers (GFAP, NFL, S100B)
Number of subjects: 1025
Study 39720677 — intervention group
Group type: EXPERIMENTAL
Intervention: Diffusion Tensor Imaging (DTI)
Number of subjects: 1025
Study 39720677 — intervention group
Group type: COMPARATOR
Intervention: Existing clinical prognostic model
Number of subjects: 1025
Study 39720838 — intervention group
Group type: EXPERIMENTAL
Intervention: LYB001
Number of subjects: 1200
Study 39720838 — intervention group
Group type: COMPARATOR
Intervention: ZF2001
Number of subjects: 1200
Study 39721059 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic elastomeric fabric orthoses (DEFOs) applied to the lower trunk and pelvis in addition to physiotherapy and rehabilitation sessions.
Number of subjects: 22
Study 39721059 — intervention group
Group type: COMPARATOR
Intervention: Conventional physiotherapy and rehabilitation program without DEFOs.
Number of subjects: 22
Study 39721062 — intervention group
Group type: EXPERIMENTAL
Intervention: Glittre activities of daily living (ADL) test
Number of subjects: 66
Study 39721066 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic Orthosis (DO)
Number of subjects: 30
Study 39721066 — intervention group
Group type: COMPARATOR
Intervention: Toe Separator (TS)
Number of subjects: 30
Study 39721752 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab and nivolumab
Number of subjects: 119
Study 39721764 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 8 mg intravenously administered at 1-hour preblock
Number of subjects: 158
Study 39721764 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 8 mg intravenously administered at the time of the block
Number of subjects: 158
Study 39721764 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 8 mg intravenously administered at 1 hour postblock
Number of subjects: 158
Study 39721764 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 8 mg intravenously administered at 2 hours postblock
Number of subjects: 158
Study 39721764 — intervention group
Group type: COMPARATOR
Intervention: Normal saline infusions (placebo)
Number of subjects: 158
Study 39721851 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipatasertib (400 mg as a single agent, starting with a single dose for 7 days and continuous daily dosing for 21 days, followed by 7 days off schedule)
Number of subjects: 14
Study 39721851 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipatasertib (400 mg)
Number of subjects: 14
Study 39722048 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular injection with electroporation
Number of subjects: 0
Study 39722048 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular injection alone
Number of subjects: 0
Study 39722048 — intervention group
Group type: COMPARATOR
Intervention: Needle-free injection system (NFIS)
Number of subjects: 0
Study 39722269 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate complete revascularization
Number of subjects: 1525
Study 39722269 — intervention group
Group type: COMPARATOR
Intervention: Staged complete revascularization
Number of subjects: 1525
Study 39722321 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced-toxicity transplant strategy with fludarabine/prednisone, treosulfan, reduced cyclophosphamide, and abatacept/sirolimus/ATG
Number of subjects: 12
Study 39722321 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced-toxicity transplant strategy
Number of subjects: 12
Study 39722333 — intervention group
Group type: EXPERIMENTAL
Intervention: Vagus nerve stimulation (sham-controlled trial)
Number of subjects: 493
Study 39722333 — intervention group
Group type: COMPARATOR
Intervention: Control group (sham)
Number of subjects: 493
Study 39722400 — intervention group
Group type: EXPERIMENTAL
Intervention: Tildrakizumab 100 mg every 12 weeks
Number of subjects: 0
Study 39722400 — intervention group
Group type: COMPARATOR
Intervention: Placebo (switched to tildrakizumab 100 mg at W16)
Number of subjects: 0
Study 39722400 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 0
Study 39722558 — intervention group
Group type: EXPERIMENTAL
Intervention: TK-OS ML models
Number of subjects: 526
Study 39722558 — intervention group
Group type: EXPERIMENTAL
Intervention: Random survival forest using TK4
Number of subjects: 526
Study 39722558 — intervention group
Group type: COMPARATOR
Intervention: Cox model
Number of subjects: 526
Study 39722560 — intervention group
Group type: EXPERIMENTAL
Intervention: MenABCWY vaccine (two doses six months apart)
Number of subjects: 0
Study 39722560 — intervention group
Group type: COMPARATOR
Intervention: MenACWY-CRM vaccine (one dose)
Number of subjects: 0
Study 39722592 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy (CRT)
Number of subjects: 2035
Study 39722592 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with atrial fibrillation (AF)
Number of subjects: 2035
Study 39722592 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with AF and non-LBBB morphology
Number of subjects: 2035
Study 39722592 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall mortality between subgroups
Number of subjects: 2035
Study 39722695 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose testosterone replacement therapy (TRT) with finasteride
Number of subjects: 0
Study 39722695 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 39723536 — intervention group
Group type: EXPERIMENTAL
Intervention: Compound 21 infusion
Number of subjects: 24
Study 39723536 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy pregnancy)
Number of subjects: 24
Study 39723608 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-administered intravaginal 5% fluorouracil (5FU) cream, 2 g every other week for eight applications.
Number of subjects: 12
Study 39723627 — intervention group
Group type: EXPERIMENTAL
Intervention: mFOLFOX6 + tucatinib + trastuzumab
Number of subjects: 0
Study 39723627 — intervention group
Group type: COMPARATOR
Intervention: Standard of care treatment (chemotherapy combination)
Number of subjects: 0
Study 39723995 — intervention group
Group type: EXPERIMENTAL
Intervention: Remotely Delivered Pelvic Yoga Program
Number of subjects: 0
Study 39723995 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 39724015 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity pulsed ultrasound with microbubbles (LIPU/MB)
Number of subjects: 0
Study 39724020 — intervention group
Group type: EXPERIMENTAL
Intervention: Active PBMT (LED therapy: DUO 240 [red at 660nm and near-infrared at 840nm] and BIOFLEX LDR-100 laser probe (660nm red light) and LD1-200 laser probe (825nm near-infrared light))
Number of subjects: 180
Study 39724020 — intervention group
Group type: COMPARATOR
Intervention: Placebo (non-effective doses of LED array and laser therapy)
Number of subjects: 180
Study 39724376 — intervention group
Group type: EXPERIMENTAL
Intervention: IMB-NIV program (6-week intervention combining in-person and telecare sessions)
Number of subjects: 124
Study 39724376 — intervention group
Group type: EXPERIMENTAL
Intervention: IMB-NIV program
Number of subjects: 124
Study 39724376 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 124
Study 39724565 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefecon
Number of subjects: 62
Study 39724565 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 39725004 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamified ABM
Number of subjects: 600
Study 39725004 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional ABM
Number of subjects: 600
Study 39725004 — intervention group
Group type: COMPARATOR
Intervention: Traditional sham ABM
Number of subjects: 600
Study 39725004 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamified ABM and Traditional ABM
Number of subjects: 600
Study 39725004 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-treatment assessments
Number of subjects: 600
Study 39725051 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo response induced through saline injection plus verbal suggestion
Number of subjects: 113
Study 39725418 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-added sugar diet (<5% of kcal from added sugars)
Number of subjects: 60
Study 39725418 — intervention group
Group type: COMPARATOR
Intervention: High-added sugar diet (≥13% kcal from added sugars)
Number of subjects: 60
Study 39725423 — intervention group
Group type: EXPERIMENTAL
Intervention: EQ-5D-5L
Number of subjects: 313
Study 39725423 — intervention group
Group type: EXPERIMENTAL
Intervention: SF-6Dv1
Number of subjects: 313
Study 39725423 — intervention group
Group type: EXPERIMENTAL
Intervention: EQ-5D-5L and SF-6Dv1
Number of subjects: 313
Study 39725450 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced nutrition package (iron and folic acid, monthly household supply of iodised salt, and micronutrient-fortified balanced energy protein supplement for undernourished women)
Number of subjects: 2399
Study 39725450 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced infection management package (genitourinary tract infection screening and treatment, and enhanced deworming)
Number of subjects: 2399
Study 39725450 — intervention group
Group type: EXPERIMENTAL
Intervention: Both enhanced nutrition and infection management packages
Number of subjects: 2399
Study 39725450 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 2399
Study 39725465 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-month online group coaching
Number of subjects: 160
Study 39725465 — intervention group
Group type: COMPARATOR
Intervention: Control group (not offered coaching)
Number of subjects: 160
Study 39725584 — intervention group
Group type: EXPERIMENTAL
Intervention: Romi-GemOxD (romidepsin, gemcitabine, oxaliplatin, and dexamethasone)
Number of subjects: 24
Study 39725764 — intervention group
Group type: EXPERIMENTAL
Intervention: Sentinel lymph node biopsy (SLNB)
Number of subjects: 208
Study 39725764 — intervention group
Group type: EXPERIMENTAL
Intervention: Wire localized lymph node biopsy (WLNB)
Number of subjects: 208
Study 39725764 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted axillary dissection (TAD)
Number of subjects: 208
Study 39725778 — intervention group
Group type: EXPERIMENTAL
Intervention: ME-344 plus bevacizumab
Number of subjects: 23
Study 39725795 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin 0.25 mg daily
Number of subjects: 60
Study 39725795 — intervention group
Group type: COMPARATOR
Intervention: Bisoprolol 5-10 mg daily
Number of subjects: 60
Study 39725891 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive assessment using the CPCog protocol including general cognitive functioning, executive functions, and visuo-motor skills.
Number of subjects: 100
Study 39725891 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplementary tests covering verbal and nonverbal short-term memory, attention, fatigue, and mental health.
Number of subjects: 100
Study 39725982 — intervention group
Group type: EXPERIMENTAL
Intervention: SB-VF plus treatment as usual (TAU) (n = 41)
Number of subjects: 172
Study 39725982 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU) (n = 38)
Number of subjects: 172
Study 39725982 — intervention group
Group type: EXPERIMENTAL
Intervention: SB-VF plus treatment as usual (TAU)
Number of subjects: 172
Study 39725988 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized perioperative blood pressure management (maintaining mean arterial pressure and systolic blood pressure at no less than 20% of baseline values)
Number of subjects: 1896
Study 39725988 — intervention group
Group type: COMPARATOR
Intervention: Conventional perioperative blood pressure management (maintaining mean arterial pressure at ≥65 mmHg and systolic blood pressure ≥90 mmHg)
Number of subjects: 1896
Study 39726097 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 39726674 — intervention group
Group type: EXPERIMENTAL
Intervention: Fumagillin
Number of subjects: 0
Study 39726877 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 PUFA supplementation
Number of subjects: 0
Study 39726877 — intervention group
Group type: COMPARATOR
Intervention: venlafaxine
Number of subjects: 0
Study 39726942 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate complete revascularization (CR)
Number of subjects: 0
Study 39726942 — intervention group
Group type: COMPARATOR
Intervention: Staged complete revascularization (CR)
Number of subjects: 0
Study 39727027 — intervention group
Group type: EXPERIMENTAL
Intervention: EC-IC bypass surgery with medical therapy
Number of subjects: 324
Study 39727027 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy (antiplatelet therapy and stroke risk factor control)
Number of subjects: 324
Study 39727053 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyridostigmine (60 mg single dose)
Number of subjects: 38
Study 39727196 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetyltransferase 2 gene (NAT2) slow acetylator status
Number of subjects: 102
Study 39727196 — intervention group
Group type: COMPARATOR
Intervention: Control group (matched for sex, age, BMI, tuberculosis diagnosis)
Number of subjects: 102
Study 39727210 — intervention group
Group type: EXPERIMENTAL
Intervention: Salsalate (part of TINSAL-T1DN trial)
Number of subjects: 525